腹膜透析患者并发症与FGF23的相关性研究
Study on the Correlation between Complications of Peritoneal Dialysis Patients and FGF23
DOI: 10.12677/acm.2025.15113262, PDF,   
作者: 王洪垚：绍兴文理学院医学院，浙江 绍兴；谢海英*：绍兴市人民医院肾内科，浙江 绍兴
关键词: FGF23；腹膜透析；血管钙化；肾性贫血；骨质疏松；炎症；FGF23； Peritoneal Dialysis； Vascular Calcification； Renal Anemia； Osteoporosis； Inflammation
摘要: 腹膜透析(PD)是终末期肾病(ESRD)的重要替代治疗手段，但PD患者死亡率居高不下，与血管钙化、肾性骨病等并发症高发密切相关，明确并发症关键调控因子是改善预后的核心。PD患者血液中成纤维细胞生长因子23 (FGF23)水平显著高于健康人群，FGF23作为骨细胞分泌的强效磷调节因子，是矿物质代谢关键枢纽，其异常升高或与PD患者磷代谢紊乱、并发症风险升高相关。当前针对PD患者FGF23与并发症之间关系的研究尚显欠缺，此领域亟待深入探索，其研究成果有望为改善PD患者的预后提供新的契机。
Abstract: Peritoneal dialysis (PD) is an important renal replacement therapy modality for patients with end-stage renal disease (ESRD); however, the mortality rate of PD patients remains persistently high, which is closely associated with the high incidence of complications such as vascular calcification and renal osteodystrophy, and identifying the key regulatory factors of these complications is crucial for improving prognosis. Levels of fibroblast growth factor 23 (FGF23) in the blood of PD patients are significantly higher than those in healthy individuals; as a potent phosphorus-regulating factor secreted by osteocytes, FGF23 serves as a key hub in mineral metabolism, and its abnormal elevation may be related to phosphorus metabolism disorders and increased risk of complications in PD patients. Currently, research on the relationship between FGF23 and complications in PD patients is still insufficient, and this field urgently requires in-depth exploration, with findings from such studies expected to provide a new opportunity for improving the prognosis of PD patients.
文章引用：王洪垚, 谢海英. 腹膜透析患者并发症与FGF23的相关性研究[J]. 临床医学进展, 2025, 15(11): 1609-1616. https://doi.org/10.12677/acm.2025.15113262

参考文献

[1] Han, N., Hong, S.H., Kim, Y.S., Kim, D.K., Kim, I., Ji, E., et al. (2017) Effect of Additive Calcium Administration on FGF23 Levels in Patients with Mild Chronic Kidney Disease Treated with Calcitriol: A Randomized, Open-Labeled Clinical Trial. Therapeutics and Clinical Risk Management, 13, 999-1007. [Google Scholar] [CrossRef] 
[2] Evenepoel, P., Meijers, B., Viaene, L., et al. (2010) Fibroblast Growth Factor-23 in Early Chronic Kidney Disease: Additional Support in Favor of a Phosphate-Centric Paradigm for the Patho-genesis of Secondary Hyperparathyroidism. Clinical Journal of the American Society of Nephrology, 5, 1268-1276.
[3] 杨悦悦, 常沁涛. FGF23在慢性肾脏病心血管并发症中的研究进展[J]. 安徽医学, 2025, 46(10): 1327-1331.
[4] Rausch, S. and Föller, M. (2022) The Regulation of FGF23 under Physiological and Pathophysiolog-ical Conditions. European Journal of Physiology, 474, 281-292. [Google Scholar] [CrossRef] 
[5] Martínez-Heredia, L., Canelo-Moreno, J.M., García-Fontana, B. and Muñoz-Torres, M. (2024) Non-Classical Effects of FGF23: Molecular and Clinical Features. International Journal of Molecular Sciences, 25, Article 4875. [Google Scholar] [CrossRef] 
[6] Chen, Y., Mao, C., Gu, R., Zhao, R., Li, W., Ma, Z., et al. (2022) Nidogen-2 Is a Novel Endogenous Ligand of LGR4 to Inhibit Vascular Calcification. Circulation Research, 131, 1037-1054. [Google Scholar] [CrossRef] 
[7] Zununi Vahed, S., Mostafavi, S., Hosseiniyan Khatibi, S.M., Shoja, M.M. and Ardalan, M. (2020) Vascular Calcification: An Important Understanding in Nephrology. Vascular Health and Risk Management, 16, 167-180. [Google Scholar] [CrossRef] 
[8] Lau, W.L., Festing, M. and Giachelli, C. (2010) Phosphate and Vascu-lar Calcification: Emerging Role of the Sodium-Dependent Phosphate Co-Transporter Pit-1. Thrombosis and Haemosta-sis, 104, 464-470. [Google Scholar] [CrossRef] 
[9] Yao, L., Sun, Y., Sun, W., Xu, T., Ren, C., Fan, X., et al. (2015) High Phosphorus Level Leads to Aortic Calcification via Β-Catenin in Chronic Kidney Disease. American Journal of Neph-rology, 41, 28-36. [Google Scholar] [CrossRef] 
[10] Vergara, N., de Mier, M.V.P., Rodelo-Haad, C., Revilla-González, G., Membrives, C., Díaz-Tocados, J.M., et al. (2023) The Direct Effect of Fibroblast Growth Factor 23 on Vascular Smooth Muscle Cell Phenotype and Function. Nephrology Dialysis Transplantation, 38, 322-343. [Google Scholar] [CrossRef] 
[11] Wesseling-Perry, K. and Jüppner, H. (2013) The Osteocyte in CKD: New Concepts Regarding the Role of FGF23 in Mineral Metabolism and Systemic Complications. Bone, 54, 222-229. [Google Scholar] [CrossRef] 
[12] 任琳. 腹膜透析患者合并贫血的相关因素分析[D]: [硕士学位论文]. 合肥: 安徽医科大学, 2020.
[13] 兰秀君. 维持性血液透析患者血FGF23水平与肾性贫血的相关性研究[D]: [硕士学位论文]. 泸州: 西南医科大学, 2018.
[14] Usui, T., Zhao, J., Fuller, D.S., Hanafusa, N., Hasegawa, T., Fujino, H., et al. (2021) Association of Erythropoietin Resistance and Fibroblast Growth Factor 23 in Dialysis Patients: Results from the Japanese Dialysis Outcomes and Practice Patterns Study. Nephrology, 26, 46-53. [Google Scholar] [CrossRef] 
[15] Honda, H., Michihata, T., Shishido, K., Takahashi, K., Takahashi, G., Ho-saka, N., et al. (2017) High Fibroblast Growth Factor 23 Levels Are Associated with Decreased Ferritin Levels and In-creased Intravenous Iron Doses in Hemodialysis Patients. PLOS ONE, 12, e0176984. [Google Scholar] [CrossRef] 
[16] Baloglu, I., Ozer, H., Ozturk, Y., Erdur, M.F., Tonbul, H.Z. and Turkmen, K. (2022) The Relationship between FGF23 and Anemia in HD and Renal Transplant Patients. Interna-tional Urology and Nephrology, 54, 1117-1122. [Google Scholar] [CrossRef] 
[17] Batchelor, E.K., Kapitsinou, P., Pergola, P.E., Kovesdy, C.P. and Jalal, D.I. (2020) Iron Deficiency in Chronic Kidney Disease: Updates on Pathophysiology, Diagnosis, and Treat-ment. Journal of the American Society of Nephrology, 31, 456-468. [Google Scholar] [CrossRef] 
[18] Farrow, E.G., Yu, X., Summers, L.J., et al. (2011) Iron Deficiency Drives an Autosomal Dominant Hypophosphatemic Rickets (ADHR) Phenotype in Fibroblast Growth Factor-23 (Fgf23) Knock-In Mice. Proceedings of the National Academy of Sciences of the United States of America, 108, E1146-E1155.
[19] Imel, E.A., Peacock, M., Gray, A.K., Padgett, L.R., Hui, S.L. and Econs, M.J. (2011) Iron Modifies Plasma FGF23 Differently in Autosomal Dominant Hypophosphatemic Rickets and Healthy Humans. The Journal of Clinical Endocrinology & Metabolism, 96, 3541-3549. [Google Scholar] [CrossRef] 
[20] Wolf, M., Koch, T.A. and Bregman, D.B. (2013) Effects of Iron Deficiency Anemia and Its Treatment on Fibroblast Growth Factor 23 and Phosphate Homeostasis in Women. Journal of Bone and Mineral Research, 28, 1793-1803. [Google Scholar] [CrossRef] 
[21] David, V., Martin, A., Isakova, T., Spaulding, C., Qi, L., Ramirez, V., et al. (2016) Inflammation and Functional Iron Deficiency Regulate Fibroblast Growth Factor 23 Production. Kidney Interna-tional, 89, 135-146. [Google Scholar] [CrossRef] 
[22] Wolf, M. and White, K.E. (2014) Coupling Fibroblast Growth Factor 23 Production and Cleavage: Iron Deficiency, Rickets, and Kidney Disease. Current Opinion in Nephrology and Hyperten-sion, 23, 411-419.
[23] Wheeler, J.A. and Clinkenbeard, E.L. (2019) Regulation of Fibroblast Growth Factor 23 by Iron, EPO, and HIF. Current Molecular Biology Reports, 5, 8-17. [Google Scholar] [CrossRef] 
[24] Zhang, Q., Doucet, M., Tomlinson, R.E., Han, X., Quarles, L.D., Collins, M.T., et al. (2016) The Hypoxia-Inducible Factor-1α Activates Ectopic Production of Fibroblast Growth Factor 23 in Tumor-Induced Osteomalacia. Bone Research, 4, Article 16011. [Google Scholar] [CrossRef] 
[25] Flamme, I., Ellinghaus, P., Urrego, D. and Krüger, T. (2017) FGF23 Expression in Rodents Is Directly Induced via Erythropoietin after Inhibition of Hypoxia Inducible Factor Proline Hy-droxylase. PLOS ONE, 12, e0186979. [Google Scholar] [CrossRef] 
[26] Coe, L.M., Madathil, S.V., Casu, C., Lanske, B., Rivella, S. and Sitara, D. (2014) FGF-23 Is a Negative Regulator of Prenatal and Postnatal Erythropoiesis. Journal of Biological Chemistry, 289, 9795-9810. [Google Scholar] [CrossRef] 
[27] Agoro, R., Montagna, A., Goetz, R., Aligbe, O., Singh, G., Coe, L.M., et al. (2018) Inhibition of Fibroblast Growth Factor 23 (FGF23) Signaling Rescues Renal Anemia. The FASEB Journal, 32, 3752-3764. [Google Scholar] [CrossRef] 
[28] Grabner, A., Amaral, A.P., Schramm, K., Singh, S., Sloan, A., Yanucil, C., et al. (2015) Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy. Cell Metabolism, 22, 1020-1032. [Google Scholar] [CrossRef] 
[29] Del Vecchio, L. and Locatelli, F. (2018) Investigational Hypox-ia-Inducible Factor Prolyl Hydroxylase Inhibitors (HIF-PHI) for the Treatment of Anemia Associated with Chronic Kid-ney Disease. Expert Opinion on Investigational Drugs, 27, 613-621. [Google Scholar] [CrossRef] 
[30] Hasegawa, H., Nagano, N., Urakawa, I., Yamazaki, Y., Iijima, K., Fujita, T., et al. (2010) Direct Evidence for a Causative Role of FGF23 in the Abnormal Renal Phosphate Handling and Vitamin D Metabolism in Rats with Early-Stage Chronic Kidney Disease. Kidney International, 78, 975-980. [Google Scholar] [CrossRef] 
[31] Francis, C. and David, V. (2016) Inflammation Regulates Fi-broblast Growth Factor 23 Production. Current Opinion in Nephrology and Hypertension, 25, 325-332. [Google Scholar] [CrossRef] 
[32] 金毅, 杨立川. 肾性贫血患者血清铁蛋白、TSAT、Cys C及维生素B12水平变化及临床意义[J]. 川北医学院学报, 2022, 37(8): 1067-1069+1085.
[33] 中国慢性肾脏病矿物质和骨异常诊治指南概要[J]. 肾脏病与透析肾移植杂志, 2019, 28(1): 52-57.
[34] Ketteler, M., Block, G.A., Evenepoel, P., Fukagawa, M., Herzog, C.A., McCann, L., et al. (2017) Executive Summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: What’s Changed and Why It Matters. Kid-ney International, 92, 26-36. [Google Scholar] [CrossRef] 
[35] 曹倩颖, 史亚男, 杨帆, 等. 血清骨硬化蛋白、骨特异碱性磷酸酶联合检测对腹膜透析患者骨质疏松的诊断价值[J]. 中国血液净化, 2024, 23(8): 581-585.
[36] 汤静, 陈蕴, 王冬雪, 等. 腹膜透析患者骨代谢与骨质疏松、腹主动脉钙化的相关性[J]. 中国骨质疏松杂志, 2023, 29(1): 52-57.
[37] 姜林森, 冯胜, 卢颖, 等. 尿毒症腹膜透析患者骨质疏松及危险因素[J]. 中国骨质疏松杂志, 2015, 21(6): 715-718.
[38] Vilaca, T., Salam, S., Schini, M., Harnan, S., Sutton, A., Poku, E., et al. (2020) Risks of Hip and Nonvertebral Fractures in Patients with CKD G3a-G5d: A Systematic Review and Me-ta-Analysis. American Journal of Kidney Diseases, 76, 521-532. [Google Scholar] [CrossRef] 
[39] Danese, M.D., Kim, J., Doan, Q.V., Dylan, M., Griffiths, R. and Chertow, G.M. (2006) PTH and the Risks for Hip, Vertebral, and Pelvic Fractures among Patients on Dialysis. American Journal of Kidney Diseases, 47, 149-156. [Google Scholar] [CrossRef] 
[40] 何贵珍. 终末期肾病透析患者血清FGF23水平与钙磷代谢及临床相关性[D]: [硕士学位论文]. 南昌: 南昌大学, 2020.
[41] 叶寅寅, 张道友, 汪裕伟. 腹膜透析患者骨密度测定与分析[J]. 皖南医学院学报, 2016, 35(5): 432-434.
[42] Bia, M., Adey, D.B., Bloom, R.D., Chan, L., Kulkarni, S. and Tomlanovich, S. (2010) KDOQI US Commentary on the 2009 KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. American Journal of Kidney Diseases, 56, 189-218. [Google Scholar] [CrossRef] 
[43] Wesseling-Perry, K., Pereira, R.C., Wang, H., Elashoff, R.M., Sahney, S., Gales, B., et al. (2009) Relationship between Plasma Fibroblast Growth Factor-23 Concentration and Bone Mineralization in Children with Renal Failure on Peritoneal Dialysis. The Journal of Clinical Endocrinology & Metabo-lism, 94, 511-517. [Google Scholar] [CrossRef] 
[44] Kanda, E., Yoshida, M. and Sasaki, S. (2012) Ap-plicability of Fibroblast Growth Factor 23 for Evaluation of Risk of Vertebral Fracture and Chronic Kidney Dis-ease-Mineral Bone Disease in Elderly Chronic Kidney Disease Patients. BMC Nephrology, 13, Article No. 122. [Google Scholar] [CrossRef] 
[45] 王涵. 微炎症状态与腹膜透析[J]. 肾脏病与透析肾移植杂志, 2012, 21(2): 183-189.
[46] Braithwaite, V., Prentice, A.M., Doherty, C. and Prentice, A. (2012) FGF23 Is Correlated with Iron Status but Not with Inflammation and Decreases after Iron Supplementation: A Supplementation Study. Inter-national Journal of Pediatric Endocrinology, 2012, Article No. 27. [Google Scholar] [CrossRef] 
[47] Munoz Mendoza, J., Isakova, T., Cai, X., Bayes, L.Y., Faul, C., Scialla, J.J., et al. (2017) Inflammation and Elevated Levels of Fibroblast Growth Factor 23 Are Independent Risk Fac-tors for Death in Chronic Kidney Disease. Kidney International, 91, 711-719. [Google Scholar] [CrossRef] 
[48] Singh, S., Grabner, A., Yanucil, C., Schramm, K., Czaya, B., Krick, S., et al. (2016) Fibroblast Growth Factor 23 Directly Targets Hepatocytes to Promote Inflammation in Chronic Kidney Disease. Kidney International, 90, 985-996. [Google Scholar] [CrossRef] 
[49] Durlacher-Betzer, K., Hassan, A., Levi, R., Axelrod, J., Silver, J. and Naveh-Many, T. (2018) Interleukin-6 Contributes to the Increase in Fibroblast Growth Factor 23 Expression in Acute and Chronic Kidney Disease. Kidney International, 94, 315-325. [Google Scholar] [CrossRef] 
[50] Zhang, X., Guo, K., Xia, F., Zhao, X., Huang, Z. and Niu, J. (2018) FGF23C-Tail Improves Diabetic Nephropathy by Attenuating Renal Fibrosis and Inflammation. BMC Biotechnology, 18, Article No. 33. [Google Scholar] [CrossRef] 
[51] 高洪志, 邓跃毅, 胡聃. FGF23/FGFR4介导的PLCγ/Calcineurin/NFAT信号通路在慢性肾衰竭微炎症状态方面的研究进展[J]. 中国中西医结合肾病杂志, 2020, 21(11): 1019-1021.
[52] Rossaint, J., Unruh, M. and Zarbock, A. (2017) Fibroblast Growth Factor 23 Actions in In-flammation: A Key Factor in CKD Outcomes. Nephrology Dialysis Transplantation, 32, 1448-1453. [Google Scholar] [CrossRef] 
[53] 牟洪宾, 周刚, 赵传燕, 等. FGF23、Klotho蛋白及Lp-PLA2水平与血液透析患者微炎症状态、钙磷代谢紊乱的关系分析[J]. 湖南师范大学学报(医学版), 2022, 19(1): 224-227.

为你推荐